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Abstract
Background: To examine whether metabotropic glutamate (mGlu) receptors have any role in mechanisms that
shape neuronal vulnerability to ischemic damage, we used the 4-vessel occlusion (4-VO) model of transient global
ischemia in rats. 4-VO in rats causes a selective death of pyramidal neurons in the hippocampal CA1 region, leaving
neurons of the CA3 region relatively spared. We wondered whether changes in the expression of individual mGlu
receptor subtypes selectively occur in the vulnerable CA1 region during the development of ischemic damage, and
whether post-ischemic treatment with drugs targeting the selected receptor(s) affords neuroprotection.
Results: We found that 4-VO caused significantly reduction in the transcript of mGlu2 receptors in the CA1 region
at times that preceded the anatomical evidence of neuronal death. Down-regulation of mGlu2 receptors was
associated with reduced H3 histone acetylation at the Grm2 promoter. The transcripts of other mGlu receptor
subtypes were unchanged in the CA1 region of 4-VO rats. Ischemia did not cause changes in mGlu2 receptor mRNA
levels in the resistant CA3 region, which, interestingly, were lower than in the CA1 region. Targeting the mGlu2
receptors with selective pharmacologic ligands had profound effects on ishemic neuronal damage. Post-ischemic oral
treatment with the selective mGlu2 receptor NAM (negative allosteric modulator), ADX92639 (30 mg/kg), was highly
protective against ischemic neuronal death. In contrast, s.c. administration of the mGlu2 receptor enhancer, LY487379
(30 mg/kg), amplified neuronal damage in the CA1 region and extended the damage to the CA3 region.
Conclusion: These findings suggest that the mGlu2 receptor is an important player in mechanisms regulating
neuronal vulnerability to ischemic damage, and that mGlu2 receptor NAMs are potential candidates in the
experimental treatments of disorders characterized by brain hypoperfusion, such as hypovolemic shock and
cardiac arrest.
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Introduction
Understanding the mechanisms underlying neuronal
vulnerability to ischemic damage may pave the way to
novel therapeutic strategies in cerebrovascular disorders.
Transient cerebral global ischemia in experimental animal
models or humans causes the degeneration of specific
populations of vulnerable neurons, such as pyramidal
neurons of the CA1 hippocampal subfield [1, 2]. Neurode-
generation develops slowly and becomes manifest only
several hours following reperfusion [2]. This relatively
long temporal window facilitates the study of the molecu-
lar mechanisms underlying the delayed ischemic neuronal
death, and allows the translation of these mechanisms into
potential therapeutic targets. One of the most widely used
animal models of transient global ischemia is the 4-vessel
occlusion (4-VO) model in rats [3]. In rats subjected
to 4-VO, CA1 pyramidal neurons tipically die at 48-72 h
after reperfusion, whereas neurons of the CA3 region and
the dentate gyrus are relatively spared, at least at this
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timepoint [4, 5]. The use of this model led to the
identification of early molecular events occurring in neu-
rons destined to die, such as derepression of the gene silen-
cer, REST [6], down-regulation of the Ca2+-impermeable
AMPA receptor subunit, GluA2 [2, 4, 7], activation of
nuclear factor-κΒ (NFκΒ) and cyclooxygenase-2 [8, 9],
and induction of the Wnt inhibitor, Dickkopf-1 [5].
These findings laid the groundwork for pharmaco-
logical studies showing that AMPA receptor antago-
nists are able to protect hippocampal CA1 neurons
against ischemic damage [10–12].
Subtype-selective ligands of metabotropic glutamate
(mGlu) receptors have shown efficacy as neuroprotective
drugs in models of transient global ischemia [13].
Pellegrini-Giampietro and collegues have consistently
shown that mGlu1, but not mGlu5, receptor antagonists
are protective against ischemic damage of CA1 pyram-
idal neurons in gerbils exposed to global ischemia and in
organotypic hippocampal slices exposed to oxygen/glucose
deprivation [14, 15, 16]. Expression and function of mGlu5
receptors are decreased in the hippocampal CA1 region at
early times after transient global ischemia [17–19], whereas
mGlu1 mRNA levels are either decreased [17] or un-
changed [18].
Mixed orthosteric agonists of mGlu2 and mGlu3 re-
ceptors (compounds LY354740 and LY379268) showed
also neuroprotective activity in the gerbil model of
transient global ischemia [20, 21], raising the import-
ant question of which of the two subtypes should be
specifically targeted by therapeutic interventions.
Interestingly, studies carried out in cultured neurons
suggest that activation of mGlu3 receptors is neuro-
protective, whereas activation of mGlu2 receptors is
not harmful under control conditions, but amplifies
neuronal damage if combined with neurotoxic insults,
such as N-methyl-D-aspartate (NMDA) [22] or β-
amyloid peptide [23]. In situ hybridization analysis in
the hippocampus of rats subjected to transient global
ischemia showed either increases [18] or reductions
[17] in mGlu2 receptor mRNA at 24 h after reperfu-
sion, with no changes in the transcript of mGlu3 re-
ceptors. Whether expression of mGlu2 and mGlu3
receptors differs in vulnerable and resistant hippo-
campal subregions in response to global ischemia is
unknown.
We now report that transient global ischemia causes
an epigenetic down-regulation of mGlu2 receptors,
which selectively occurs in the vulnerable CA1 region.
Post-ischemic treatment with a selective negative allo-
steric modulator (NAM) of mGlu2 receptors pro-
tected CA1 neurons against ischemic damage,
whereas treatment with a positive allosteric modulator
(PAM) of mGlu2 receptors extended ischemic damage
to CA3 neurons.
Results
Temporal profile of neuronal damage in CA1 and CA3
regions in rats subjected to transient global brain
ischemia
Transient global ischemia induced by 4-VO in rats
caused the expected loss of CA1 pyramidal neurons at
72 h following reperfusion, with no detectable neuronal
death at 6, 12, or 24 h (images at 24 and 72 h are shown
in Fig. 1). Neurons of the CA3 region and the dentate
gyrus were largely resistant to ischemic damage, at least
at 72 h after reperfusion (Fig. 1).
Global ischemia caused an early down-regulation of
mGlu2 receptors in the CA1 region
We measured the transcripts of mGlu1, mGlu2, mGlu3,
and mGlu5 receptors by qPCR in microdissected CA1
and CA3 regions of sham-operated and 4-VO rats at
times that preceded neuronal death (12 and 24 h after
reperfusion). We were surprised to find that sham-
operated rats showed much lower mGlu2 mRNA levels
in CA3 than in CA1 region at both times (Fig. 2a). This
distribution pattern was unique to mGlu2 receptors, at
least with respect to mGlu1, mGlu3, and mGlu5 recep-
tors (Fig. 2b-d). 4-VO Rats showed a substantial de-
crease in mGlu2 mRNA levels in the CA1 region, with
no changes in the CA3 region. This reduction was more
prominent at 24 h than at 12 h after reperfusion (-57 %
and -46 % vs. the respective values of sham-operated
rats, respectively) (Fig. 2a). Ischemia did not cause sig-
nificant changes in mGlu1, mGlu3, and mGlu5 receptor
mRNA levels in the two hippocampal subregions
(Fig. 2b-d). At 24 h, mGlu1 mRNA levels were higher in
CA3 than in CA1 region in both sham-operated and is-
chemic rats (Fig. 2c).
Global ischemia up-regulated HDAC2 and reduced histone
acetylation in the mGlu2 receptor gene promoter in the
CA1 region at times that precede neuronal death
In order to dissect the epigenetic programming leading to
changes in the expression of mGlu2 receptors in response
to global ischemia, we measured the transcript encoding
for type-1 and type-3a DNA-methyltransferases (Dnmt1
and -3a) and type-1, -2, and -3 histone deacetylases
(Hdac1, -2 and -3) in the CA1 and CA3 regions in 4-VO
rats at 6, 12, and 24 h after reperfusion and at correspond-
ing times in sham-operated rats. We also measured the
transcript of Gadd45β, which is the product of a DNA-
damage responsive gene and is involved in mechanisms of
DNA demethylation [24–26], and the transcript of the
glucocorticoid receptor (GR, encoded by the Nr3c1 gene),
which is known to regulate the expression of Hdac2 [27].
Transient global ischemia caused a selective increase in
the transcripts of Hdac2 and GRs in the vulnerable CA1
region at 12 h after reperfusion (Fig. 3b, c). The transcript
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encoding for Gadd45β was strongly up-regulated at early
times after reperfusion (6 and 12 h) in both CA1 and CA3
(Fig. 3d; see also ref. [28]), suggesting that the resistant
CA3 region was also reactive to the ischemic insult at
early times after reperfusion. The transcripts of Dnmt1
and Dnmt3a did not change in CA1 in response to global
ischemia. Increases in Dnmt3a mRNA levels were only
observed in the CA3 region at 6 h after ischemia (Fig. 3a).
Hdac1 and Hdac3 mRNA levels did no change in CA1 of
4-VO rats. We only found a reduction of Hdac1 mRNA
levels in CA3 at 24 h after ischemia with respect to the
corresponding group of sham-operated rats (Fig. 3b).
Knowing that the mGlu2 receptor gene (Grm2) gene pro-
moter is targeted by HDAC2 [29], we extended the analysis
to the HDAC2 protein levels and to histone H3 acetylation
at the mGlu2 receptor gene promoter in the CA1 region at
12 and 24 h after reperfusion. Immunoblot analysis showed
a significant increase in HDAC2 protein levels at 12 h, and
a reduction at 24 h after reperfusion (Fig. 4a). ChIP analysis
of acetylated-H3 histone bound to the Grm2 promoter
showed a trend to a reduction (-50 %) at 12 h, and a signifi-
cant reduction (-53 %) at 24 h after reperfusion (Fig. 4b).
Effect of post-ischemic treatment with selective mGlu2
receptor ligands on neuronal damage in 4-VO rats
Because orthosteric ligands do not differentiate between
mGlu2 and mGlu3 receptors, we used two brain per-
meant allosteric modulators to specifically examine the
influence of mGlu2 receptors on neurodegeneration/
neuroprotection in the 4-VO model of transient global
ischemia. As a selective mGlu2 PAM, we used a com-
mercially available compound (LY487379), which has no
intrinsic agonist activity at mGlu2 receptors, but markedly
potentiates glutamate-evoked responses at mGlu2 recep-
tors [30, 31]. To selectively inhibit mGlu2 receptors, we
used compound ADX92639, the characterization of which
is reported below.
In vitro pharmacological profile of ADX92639
Compound ADX92639 was tested in an agonist or antag-
onist mode with a FLIPR-based intracellular Ca2+
mobilization assay using HEK293 cells stably expressing
rat or human recombinant mGlu receptor subtypes.
ADX92639 exhibited a high potency as an mGlu2 receptor
antagonist, with apparent IC50 values of 175 nM and 145
nM at human and rat mGlu2 receptor clones, respectively
(Fig. 5a). The potency as an antagonist of ADX92639
at human mGlu3 receptor clones was 100 fold lower
(IC50 value = 17.4 μM) (Fig. 5a). The compound had no
activity as an agonist, antagonist, PAM or NAM at all
other mGlu receptor subtypes (data not shown). In
addition, ADX92639 was inactive up to 10 μM in compe-
tition binding assay on membranes expressing 71 G-
protein coupled receptors, transporters, enzymes, and ion








Fig. 1 Temporal profile of neuronal damage in CA1 and CA3 hippocampal regions. Representative Nissl staining of the CA1 and CA3 regions of
rats subjected to 4-VO at different times after reperfusion (24 and 72 h)
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Schild-plot experiments carried out in human
mGlu2 receptor clones showed that ADX92639 induced a
rightward shift of the glutamate concentration-response
curve (in the FLIPR assay) together with a decrease in glu-
tamate efficacy (Fig. 5b). This profile is consistent with a
NAM activity of ADX92639 at mGlu2 receptors. Revers-
ibility experiments (Fig. 5c) showed that the effect of
ADX92639 observed in the Schild-plot analysis was not
due to a non-reversible competitive effect of the
compound.
The non competitive nature of the antagonist activ-
ity of ADX92639 was confirmed by competition experi-
ments using [3H]LY341495, in which ADX92639 was
unable to displace specifically bound [3H]LY341495 to
membranes from human mGlu2 receptor clones, as op-
posed to LY341495 and glutamate (Fig. 5d).
Repeated treatment with ADX92639 did not cause
changes in body temperature in rats
Knowing that mGlu2 receptor ligands may cause
changes in body temperature [32–35] we measured body
temperature in rats after oral administration of
ADX92639 or its vehicle. ADX92639 or vehicle was ad-
ministered three times with intervals of 24 h. Values of
body temperature, collected at different times from 1
to 58 h after the first administration, did not differ
between the groups of rats treated with ADX92639
and vehicle. In none of the timepoints values were
lower than 35.8 °C in both groups of rats (Table 1).
Treatment with the mGlu2 receptor negative allosteric
modulator, ADX92639, protected CA1 neurons against
ischemic damage, whereas treatment with the mGlu2
receptor enhancer, LY487379, extended ischemic damage
to CA3 neurons
In a first set of experiments, 4-VO rats were treated
orally with 30 mg/kg of ADX92639 or vehicle at 12,
36, and 60 h after reperfusion. Sham-operated rats
were only treated with vehicle. CSF exposure of
ADX92639 after an oral dose of 30 mg/kg is largely
(4 fold) above the in vitro IC50 value at the mGlu2
receptor; in addition, 30 mg/kg is the dose of
ADX92639 that has previously shown to produce
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Fig. 2 Expression profile of mGlu receptors in CA1 and CA3 regions at times preceding neuronal death. Quantitative PCR analysis of (a) mGlu2,
(b) mGlu3, (c) mGlu1 and (d) mGlu5 receptors (mGluR1, -2, -3, and -5) at 12 and 24 h after reperfusion. mRNA values, expressed as copy number,
were normalized to β-actin and are means ± S.E.M. of 3-5 rats per group; One-way ANOVA + Fisher's LSD: In (a) mGluR2 at 12 h post ischemia:
F(3,15) = 7.6, p < 0.05; mGluR2 at 24 h post ischemia: F(3,15) = 7.1, p < 0.05; in (b) mGluR3 at 24 h: F(3,14) = 2.6, p < 0.05; in (c) mGluR1 at 24 h post
ischemia: F(3,14) = 9.2, p < 0.05. Post-hoc analysis: p < 0.05 vs. the respective values obtained in sham operated rats (*); or vs. the respective values
obtained in the CA1 region (#)
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cognition [36]. Treatment with ADX929639 in 4-VO
rats was highly protective against ischemic neuronal
death in the CA1 region at 72 h after reperfusion. As
expected, global ischemia did not cause detectable
changes in the number of viable neurons in the CA3
region, regardless of treatment with ADX92639
(Fig. 6a, b).
Additional groups of 4-VO rats were treated s.c. with
the mGlu2 PAM, LY487379 (30 mg/kg) or vehicle at 12,
24, 36, 48, and 60 h after reperfusion. Sham-operated
rats were also treated with LY487379 or vehicle at the
corresponding times. Treatment with LY487379 in 4-VO
rats caused a non-significant trend to the amplification
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Fig. 3 Gene expression analysis of epigenetic factors following global ischemia at several times preceding neuronal death. Quantitative PCR
analysis of (a) Dnmt1 and Dnmt3a, (b) Hdac1, Hdac2 and Hdac3, (c) Nr3c1 and (d) Gadd45β, at 6, 12 and 24 h after reperfusion. mRNA values,
expressed as copy number, were normalized to β-actin and are means ± S.E.M. of 3-5 individual determinations; One-way ANOVA + Fisher's LSD.
In (a) Dnmt3a at 6 h: F(3,15) = 9.3, p < 0.05; In (b) Hdac1 at 6 h: F(3,17) = 4.8, p < 0.05; at 24 h: F(3,15) = 3.8, p < 0.05; Hdac2 at 12 h: F(3,13) = 4.6, p < 0.05;
Hdac3 at 6 h: F(3,17) = 2.9, p < 0.05; in (c) Nr3c1 at 6 h: F(3,17) = 4.3, p < 0.05; Nr3c1 at 12 h: F(3,14) = 5.165 p < 0.05 and in (d) Gadd45β at 6 h: F(3,17) = 48.4,
p < 0.0001, at 12 h: F(3,13) = 8.6 p < 0.005. Post-hoc analysis: p < 0.05 vs. the respective values obtained in sham operated rats (*); or vs. the respective
values obtained in the CA1 region (#)
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extended ischemic damage to the CA3 region (Fig. 6c,
d). The two sham-operated rats treated with LY487379
showed no signs of neuronal death in the CA1 region
(number of viable neurons = 10,601 and 9599/mm2) with
respect to sham-operated rats treated with vehicle (see
Fig. 6c), suggesting that the compound was not neuro-
toxic on its own (i.e., in the absence of ischemia).
Discussion
The Grm2 gene encoding the mGlu2 receptor is highly
plastic and undergoes epigenetic modifications in re-
sponse to environmental stressors and drug treatments.
For example, exposure to prenatal stress, activation of
mineralcorticoid receptors by corticosterone, and treat-
ment with atypical antipsychotic drugs all cause an epi-
genetic down-regulation of mGlu2 receptors in forebrain
regions, such as the hippocampus and frontal cortex [29,
37, 38]. Expression of mGlu2 receptors is heavily
regulated by acetylation mechanisms [38–41], and
HDAC2 in particular was found to bind to the Grm2
promoter and inhibit mGlu2 receptor expression [29]. A
high sensitivity to epigenetic regulation is a distinct fea-
ture of the mGlu2 receptor. Of note, the mGlu3 recep-
tor, which shares structural and functional similarities
with the mGlu2 receptor, is less susceptible to epigenetic
regulation [29, 37, 40].
Present data offer the first demonstration that a spe-
cific insult (transient global ischemia) causes epigenetic
changes in mGlu2 receptors that might be related to
mechanisms of neurodegeneration/neuroprotection. Ex-
pression of mGlu2 receptors in the CA1 region was
down-regulated in response to ischemia at times that
preceded the anatomical evidence of neuronal death.
Histone acetylation at the Grm2 promoter was also
reduced in CA1 at early times after reperfusion (12
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Fig. 4 HDAC2 protein levels and Grm2 promoter H3-acetylation in the CA1 region following global ischemia. (a) Western blot analysis of HDAC2
in CA1 region at 12 and 24 h after reperfusion. Values are means ± S.E.M of 3-6 rats per group * p < 0.05 (Student's t test) vs. sham-operated rats;
t(7) = 2.73 and t(7) = 2.61 at 12 and 24 h, respectively. (b) Chip analysis of H3 histone acetylation of Grm2 promoter in CA1 region at 12 and 24 h
after reperfusion. Values (percent of input) are expressed as percent of controls (sham-operated), and are means ± S.E.M. of 3-8 rats per group.
*p < 0.05 (Student's t-test) vs. sham-operated rats; t(5) = 1.43 and t(13) = 2.67 at 12 and 24 h, respectively
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activator, GR [27], showed an early up-regulation (12 h)
following reperfusion. HDAC2 levels decreased in the
CA1 region at 24 h after reperfusion perhaps as a result of
a negative feedback regulation. These data suggest the fol-
lowing scenario: transient global ischemia causes the GR-
mediated induction of HDAC2, which, in turn, associates
with the Grm2 gene promoter causing a long-lasting his-
tone deacetylation and inhibition of gene expression. After
global ischemia, the mGlu2 receptor was down-regulated
in the vulnerable CA1 region, but not in the resistant CA3
region. This raised two questions that may be relevant to
the study of selective neuronal vulnerability to ischemic
damage: (i) is the down-regulation of mGlu2 receptors
neurotoxic or neuroprotective?; (ii) why is the mGlu2 re-
ceptor specifically down-regulated in the CA1 region after
ischemia? Studies carried out in neuronal cultures chal-
lenged with excitotoxins or β-amyloid peptide suggest that
activation of mGlu2 receptors is detrimental to neurons at
least within the context of a neurodegenerative process
[22, 23]. Present data are fully consistent with this hypoth-
esis. We used a NAM (compound ADX92639), which
showed a high degree of selectivity for mGlu2 receptors
and did not cause changes in body temperature following
systemic administration. ADX92639, given orally several
hours after reperfusion, was highly protective against CA1
damage. In contrast, pharmacological enhancement of
mGlu2 receptors with the selective PAM, LY487379, in-
creased neuronal damage. This suggests that the epigen-
etic down-regulation of mGlu2 receptors occurring in the
CA1 region at 12-24 h after reperfusion represents a po-
tential defensive mechanism. However, the residual activ-
ity of mGlu2 receptors still contributes to the progression
of neuronal damage unless the receptor is pharmacologic-
ally inhibited in the post-ischemic period.
The specificity of mGlu2 receptor changes for the
CA1 region could be simply explained by assuming that
it is only this region that is sensitive to ischemic insult.
However, global ischemia caused an early up-regulation
of the death-related protein, GADD45β, in both CA1
and CA3 (see also ref. [28]). This suggests that a death
gene program is induced in both vulnerable and resistant
neurons after global ischemia, and that resistant neurons
harbor a molecular repertoire that restrains the develop-
ment of the program. We were surprised to find that
mGlu2 receptor mRNA levels were much lower in CA3















































































Glutamate @ 300 μM [Ctrl]
ADX92639 no wash
ADX92639+ wash
Fig. 5 In vitro pharmacological profile of the mGlu2 receptor NAM ADX92639. FLIPR data are shown in (a-c). Concentration-response curves of
ADX92639 in HEK293 cells stably expressing human or rat mGlu2 receptors or human mGlu3 receptor and challenged with glutamate at the EC80
value are shown in (a). Schild-plot analysis carried out in human mGlu2 cells challenged with glutamate in the absence or presence of increasing
concentrations of ADX92639 is shown in (b). A reversibility experiment is shown in (c), where human mGlu2 receptor cells were treated with increasing
concentrations of ADX92639 before being either washed or not prior to the addition of an EC80 of glutamate. [
3H]LY341495 (1 nM) binding in membrane
prepared from human mGlu2 clones incubated in the absence or presence of increasing concentrations of ADX92639, glutamate or non-radioactive
LY341495 is shown in (d). Values are means ± SD of two replicates per point and curves are representative of one from 2 to 6 separate experiments
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response to ischemia. The low expression of mGlu2 re-
ceptors might contribute to the intrinsic resistance of
CA3 neurons to ischemic damage unless the function of
these receptors is pharmacologically amplified at critical
time windows after reperfusion. This explains why post-
ischemic treatment with the mGlu2 receptor PAM,
LY487379, extended neuronal death to the CA3 region,
which was otherwise resistant. We wish to highlight that
LY487379 did not cause any apparent sign of neuronal
toxicity in non-ischemic rats, suggesting that pharmaco-
logical activation of mGlu2 receptor is not toxic per se
but may play a permissive role on neuronal damage in
the presence of an ischemic insult.
The molecular mechanism by which activation of
mGlu2 receptors becomes detrimental for neurons com-
mitted to die is unknown. mGlu2 receptors are coupled
to Gi/Go proteins and their activation leads to inhibition
of adenylate cyclase activity and inhibition of voltage-
sensitive Ca2+ channels with ensuing reduction of
neurotransmitter release [42]. It is possible that either
inhibition of GABA release from CA1 interneurons
[43, 44] or activation of intracellular death-related
mechanisms in pyramidal neurons are involved in the
permissive role of mGlu2 receptors on neuronal dam-
age. However, our analysis of Grm2 expression was
not carried out at cellular level, and we cannot ex-
clude that mGlu2 receptors present in cells other
than pyramidal neurons are involved in the patho-
physiology of ischemic neuronal death and can be
targeted by neuroprotective drugs. For example, in-
flammatory mechanisms and microglial activation
contribute to neuronal degeneration in models of
transient global ischemia, including the 4-VO model
[45–47]. mGlu2 receptors are present in microglia
[48, 49], and activation of mGlu2 receptors induces a
pro-inflammatory and neurotoxic phenotype in micro-
glia [48, 50, 51]. Microglial cells respond to mGlu2
receptor activation with an enhanced production of
tumor-necrosis factor-α and other mechanisms that
are detrimental to neighbor neurons [50, 51]. On the basis
of data obtained in an in vitro model of oxygen-glucose
deprivation, it has been suggested that activation of micro-
glial mGlu2 receptors by the glutamate released from is-
chemic neurons may contribute to the overall process of
neuronal death [51]. Thus, it cannot be excluded that
mGlu2 receptor blockade in microglia might have contrib-
uted to the protective effect of ADX92639 we have seen in
the 4-VO model.
Our findings raise the possibility that mGlu2 receptor
NAMs might be helpful in the treatment of cardiac ar-
rest, hypovolemic shock, severe hypotension or other
pathologies that may reduce brain perfusion below a
critical threshold and cause damage of vulnerable hippo-
campal neurons. To support this possibility it will be im-
portant to extend the study to other mGlu2 receptor
NAMs and also to induce transient global ischemia in
rats lacking mGlu2 receptors [52, 53]. Of note, preclin-
ical studies show that mGlu2 receptor NAMs have a po-
tential therapeutic value in the treatment of cognitive
dysfuntion associated with major depression, which is
often resistant to conventional antidepressant medica-
tion [54, 55]. The neuroprotective effect of mGlu2 re-
ceptor NAMs may be an added value if these drugs are
used for the treatment of depression associated with vas-
cular dementia or chronic cardiovascular disorders caus-
ing brain hypoperfusion and neuronal damage.
Conclusions
We found that the mGlu2 receptor was epigenetically
down-regulated in the vulnerable CA1 region during the
development of ischemic damage. This change might
represent a protective mechanism aimed at restraining
ischemic neuronal damage, because post-ischemic treat-
ment with an mGlu2 receptor NAM reduced the extent
of ischemic damage. These findings may be relevant in
the mGlu receptor field for three reasons. First, they
suggest that expression of mGlu2 receptors undergoes
plastic changes under pathological conditions and this
mechanism might be related to the intrinsic vulnerability
of particular neuronal populations to ischemic damage.
Second, they are in line with previous findings from our
group demonstrating that pharmacological activation of
mGlu2 receptors, which is safe under normal conditions,
Table 1 Effects of ADX92639 or its vehicle on body
temperature at different times (1-58 h) after first administration
Hours Vehicle ADX92639
0 36.9 ± 0.3 37.0 ± 0.1
1 36.4 ± 0.3 36.5 ± 0.3
3 35.9 ± 0.1 36.1 ± 0.1
6 35.8 ± 0.1 35.8 ± 0.1
9 37.0 ± 0.1 36.9 ± 0.2
24 36.2 ± 0.1 36.2 ± 0.4
25 35.9 ± 0.0 35.8 ± 0.1
27 35.9 ± 0.0 35.9 ± 0.1
30 36.2 ± 0.2 36.3 ± 0.2
33 36.8 ± 0.3 36.1 ± 0.2
48 36.0 ± 0.1 35.9 ± 0.0
49 36.1 ± 0.0 36.1 ± 0.0
52 36.1 ± 0.1 36.1 ± 0.1
55 36.2 ± 0.0 36.2 ± 0.1
58 36.7 ± .03 36.5 ± 0.3
Effect of oral treatment with ADX92639 (30 mg/kg) or vehicle on body
temperature in normal rats. ADX92639 or vehicle were administered three
times with 24 h of interval. Rectal temperature was measured at different
times (1-58 h) after the first administration of ADX92639 or vehicle. Value are
means ± S.E.M. (n = 3)
Motolese et al. Molecular Brain  (2015) 8:66 Page 8 of 13
may be detrimental to neurons challenged by a toxic in-
sult. Third, and more important, they suggest that se-
lective mGlu2 receptor NAMs may be beneficial in the
treatment of brain ischemia or hypoperfusion.
Materials and methods
Induction of transient global ischemia in rats
Adult male Sprague Dawley rats (Charles River, Calco,
Italy), weighing 200-250 g, were housed under controlled
conditions (ambient temperature, 22 °C; humidity, 40 %)
on a 12 h light-dark cycle with food and water ad libi-
tum. Animal experiments were performed in full compli-
ance with the ARRIVE guidelines. All efforts were made
to minimize the number of animals and animal suffering.
The experimental protocol was approved by the Ethical
Comittee of Neuromed Institute (Pozzilli, Italy) and by
The Italian Ministery of Health (D.M. 227/2011-B).
Transient global ischemia was induced by the 4-VO
method [3], as described previously [5] with minor mod-






















































































































Fig. 6 Neuronal damage analysis of post-ischemia treatment with an mGlu2 receptor NAM, ADX92639, or PAM, LY487379. Nissl staining and neuronal
density in the CA1 and CA3 regions of sham-operated and 4-VO rats treated with selective mGlu2 receptor ligands. In (a) and (b), vehicle or the mGlu2
receptor NAM, ADX92639 (30 mg/kg), were orally administered three times at 12, 36, and 60 h after reperfusion; sham-operated rats were only treated
with vehicle. Rats were killed at 72 h after reperfusion. Values are means ± S.E.M. of 3-8 rats per group. p < 0.05 vs. sham-operated rats (*) or vs. 4-VO rats
treated with vehicle (#) (One-way ANOVA+ Fisher LSD, F(2,18) = 10). In (c) and (d), vehicle or the mGlu2 receptor PAM, LY487379 (30 mg/kg), were s.c.
injected five times at 12, 24, 36, 48 and 60 h after reperfusion. Sham-operated rats were only treated with vehicle (data of two sham-operated rats
treated with LY487379 are reported in the Results section). Rats were killed at 72 h after reperfusion. Values are means ± S.E.M. of 3-5 rats
per group. p < 0.05 vs. sham-operated rats (*) or vs. 4-VO rats treated with vehicle (#) (One-way ANOVA + Fisher LSD; CA1: F(2,12) = 29.7,
p < 0.05; CA3 : F(2,12) = 5.9, p < 0.05)
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chloral hydrate (350 mg/kg, i.p.), and positioned in a
stereotaxic apparatus with the head tilted down at ap-
proximately 30° from the horizontal plane; an incision
was made behind the occipital bone directly overlying
the first two cervical vertebrae. The paraspinal muscles
were separated from the midline, and the right and the
left alar foramina of the first cervical vertebrae were ex-
posed. A 0.5 mm electrocautery needle was inserted
through each alar foramen, and both vertebral arteries
were electrocauterized and permanently occluded.
Afterwards, both common carotid arteries were ex-
posed and isolated with a 3-0 silk tread, and the inci-
sion was sutured. Twenty-four hours later, animals
were anesthetized with isofluorane (induction, 3 %;
maintenance, 2 %), the wound was reopened, and both
common carotid arteries were occluded with aneuris-
mic clips for 10 min. Anesthesia was temporarily dis-
continued during carotid artery occulsion. Only rats
showing complete loss of consciousness with loss of
righting reflex and bilateral midriasis were included in
the study. After 10 min of occlusion, isoflurane
anesthesia was restored, both carotid arteries were reo-
pened and visually inspected to ensure adequate reflow,
and the wound was sutured. Body temperature was moni-
tored and manteined at 37 °C with rectal thermistor
coupled to a heating blanket. After reperfusion, animals
were kept for 2 h at 37 °C before being treansferred to
their home cages. For sham operation, animals were sub-
jected to the same anesthesia and surgical procedures,
except that carotid arteries were not occluded.
Biochemical analysis
Animals were killed by decapitation at 6, 12, 24, and 72
h after reperfusion. The brain was quickly removed and
placed on an ice-cold rat brain matrix. A 2-mm thick
slice containing the dorsal hippocampus was rapidly re-
moved, and the CA1 and CA3 subfileds were microdis-
sected on ice under stereomicroscope, immediately
frozen on liquid nitrogen, and stored at -80 °C.
RNA isolation, reverse transcription and qPCR
Total RNA from CA1 and CA3 hippocampal regions was
extracted using Trizol reagent (Invitrogen) according to
manufacturer’s protocol. The RNA was then treated with
DNAse (Qiagen) and single strand cDNA was synthesized
from 2 μg of total RNA using superscript III (Invitrogen)
and random hexamers. Real-time PCR was performed on
20 ng of cDNA by using specific primers and Power SYBR
Green Master Mix (Applied Biosystem) on an Applied
Biosystems Step-One instrument. Thermal cycler condi-
tions were as follows: 10 min at 95 °C, 40 cycles of de-
naturation (15 sec at 95 °C), and combined annealing/
extension (1 min at 60 °C). Primers used were as follows:
Hdac1 Forw CTGTCCGGTATTTGATGGCT and Rev
TCAGACTTCTTCGCATGGTG; Hdac2 Forw AGGTC
GTAGGAATGTCGCTG and Rev GATTTGGCTCCTTT
GGTGTC; Hdac3 Forw CCAGAAGCACCCAATGAATT
and Rev TTCCAAACCCGTTACCAGAG; mGlu1 recep-
tor Forw CATACGGAAAGGAGAAGTGA and Rev AAA
AGGCGATGGCTATGATA; mGlu5 receptor Forw GCT
GTGAGATCAGAGATTCCTGC and Rev ACTCCCAC
TATGGGTTTCTTGG; mGlu2 receptor Forw GCTGC
TCCAAGGATACAC and Rev ATAGCTGATCTGTGGG
ATCT; mGlu3 receptor Forw CAAGTGACTACAGAGT
GCAG and Rev CTGTCACCAATGCTCAGCTC; Dnmt1
Forw TGTCCTGTCGTCTGCAACCT and Rev GCCATC
TCTTTCCAAGTCTTT; Dnmt3a Forw CCATGCCAAG
ACTCACCTTC and Rev GCTTTCTTCTCAGCCTCC
CT; Nr3c1 Forw CCATCGTCAAAAGGGAAGGG and
Rev CAGCTAACATCTCTGGGAAT; Gadd45β Forw GC
TGGCCATAGACGAAGAAG and Rev GCCTGATACC
CTGACGATGT; and β-actin Forw GTTGACATCCGT
AAAGACC and Rev TGGAAGGTGGACAGTGAG.
mRNA copy number of each gene analyzed was calcu-
lated from serially diluted standard curves simultan-
eously amplified with the samples and normalized
against β-actin copy number.
Chromatin immunoprecipitation
Chromatin immunoprecipitation assay was performed
by standard procedures. Briefly, tissue was cross-linked
using 1 % formaldehyde at room temperature for 10
min. The crosslinking reaction was stopped by adding
glycine to a final concentration of 0.125 M. Tissue was
then washed three times with ice-cold PBS supple-
mented with protease inhibitors (Sigma-Aldrich), ho-
mogenized in lysis buffer (5 mM PIPES pH 8.0, 85 mM
KCl, 0.5 % NP40, protease inhibitors), and nuclei lysis
buffer (1 % SDS, 10 mM EDTA, 50 mM Tris-HCl pH
8.0, protease inhibitors), and then sonicated on ice using
a Covaris S220 ultrasonicator. Following sonication,
chromatin fragments of 0.2-0.6 kb in length were ob-
tained. Ten percent of the sonicated lysate was saved
and successively used to quantify the total amount of
DNA present in different samples before immunoprecip-
itation (Inputs). The chromatin solution was precleared
with salmon sperm DNA/protein A-agarose 50 % gel
slurry for 1 h at 4 °C and immunoprecipitated overnight
at 4 °C with antibodies against acetyl-histone H3 (Up-
state) or the respective isotype matched control Ig. After
precipitation, the chromatin-antibody complexes were
collected using Protein A Sepharose beads and washed.
Samples were then eluted with 1 % SDS, 100 mM
NaHCO3 at room temperature for 15 min, reverse
cross-linked with NaCl 100 mM at 65 °C overnight, and
treated with proteinase-K. Protein-free DNA was ex-
tracted by phenol/chloroform/isoamyl alcohol, precipi-
tated with 100 % ethanol, and analyzed by real-time PCR
Motolese et al. Molecular Brain  (2015) 8:66 Page 10 of 13
using the following specific primers for Grm2 promoter:
Forw GATCTGCTGGAAGCTGCTG and Rev CCTCC
TCTGTTCCTCTGGACT. Levels of histone acetylation
at the mGlu2 receptor gene promoter were expressed as
percentage of the input DNA that was immunoprecipitated
by the anti acetyl-histone H3 antibody using the following
equation: % (acetDNA ‐ IP/total input) = 2 ^ [(Ct(10 % in-
put) ‐ 3.32) ‐ Ct(acetDNA ‐ IP)] × 100 %.
Western blot analysis
CA1 regions were dissected and homogenized at 4 °C in
a buffered solution composed of Tris-HCl pH 7.5, 10
mM; NaCl, 150 mM; SDS 10 %, EDTA, 5 mM; PMSF, 10
mM; IGEPAL, 1 %; leupeptin, 1 μg/ml; and aprotinin, 1
μg/ml. Equal amounts of proteins (30 μg) from superna-
tants were separated by 10 % SDS polyacrilamide. After
separation, proteins were transferred on immuno-blot
PVDF membranes. Membranes were incubated with a
mouse monoclonal anti-HDAC2 antibody (1:5,000, over-
night at 4 °C, Upstate), and then incubated for 1 h with
an anti-mouse secondary antibody (1:7000, peroxidase-
coupled). Immunostaining was revealed by the enhanced
ECL Western blotting analysis system (Hybond ECL, GE
Healthcare Europe). The blots were reprobed with anti-
β-actin monoclonal antibody (1:60,000; Sigma) followed
by an anti-mouse antibody (1:7,000; Calbiochem). Densi-
tometric analysis was performed with Quantity One soft-
ware (Bio-Rad).
Histological analysis
Animals were killed at 24 or 72 h after reperfusion.
Brains were fixed in Carnoy’s solution, embedded in par-
affin, and sectioned at 10 μm. Sections were deparaffi-
nized and processed for staining with thionin (Nissl
staining) for histologic assessment of neuronal degener-
ation. Surviving neurons were counted in the CA1 and
CA3 hippocampal subfield under a light microscope at
20× magnification. Neurons with a rounded shape simi-
lar to that commonly observed in sections from control
animals were considered to be viable. Cells were counted
from three sections of the dorsal hippocampus within a
dissector area of 1,225 μm2 (35 × 35 μm) randomly posi-
tioned by the software (Image pro plus 6.0) over the re-





(LY487379) was purchased from Tocris. ADX92639,
was provided from Addex Therapeutics. The molecu-
lar structure of ADX92639 could not be disclosed by
Addex. General features of compound ADX92639 are
the following: molecular weight = 332; partition
coefficient (ClogP) = 1.8; topographical polar surface
area (tPSA) = 79 Ȧ; H-bond donor/H-bond acceptor
(HBD/HBA) = 0/6; kinetic solubility at pH 7.4 = 0.137
mg/ml; intrinsic clearance (Clint) in rats = 12 μl/min/
mg prot.
Characterization of the receptor profile of ADX92639
FLIPR-based intracellular Ca2+ mobilization assay
A fluorescent cell-based Ca2+ mobilization assay was
performed on HEK293 cells stably expressing rat or hu-
man recombinant mGlu receptor subtypes, as described
previously [56]. ADX92639 was tested at different con-
centrations, up to 30 μM, as an agonist, positive allo-
steric modulator (PAM), or negative allosteric modulator
(NAM). ADX92639 was also tested in competition bind-
ing assay on membranes expressing 71 targets including
G-protein coupled receptors, membrane transporters,
enzymes, and ion channels (Cerep, Poitiers, France). In a
Schild-plot analysis in mGlu2 receptor-expressing cells,
the concentration-response curve to glutamate was
tested in the presence of increasing concentrations of
ADX92639. To assess the reversibility of the effect of
ADX92639, cells expressing the mGlu2 receptor were
treated with the compound and then either washed
three times with PBS or not. Cells were then stimulated
with glutamate at the EC80 value.
[3H]LY341495 binding on membranes from cells
expressing human mGlu2 receptor
For the study of [3H]LY341495 binding, we used the same
buffer and conditions described by Wright et al. (2001).
Cell membrane homogenates were washed three times
with ice-cold assay buffer (10 mM potassium phosphate
buffer containing 100 mM potassium bromide, pH 7.6).
Potassium bromide was added because bromide ions are
known to enhance [3H]LY341495 binding [57]. Mem-
branes were incubated in the presence of 1 nM
[3H]LY341495 at 5 °C for 30 min in the presence of in-
creasing concentrations of non-radioactive LY341495, glu-
tamate, or ADX92639. Bound and free [3H]LY341495
were separated by filtration.
Measurements of body temperature in rats treated with
ADX92639
The effect of ADX92639 on body temperature was mea-
sured in male Sprague-Dawley rats of the same age and
weight of those used for the induction of global is-
chemia. Rats were treated orally with either
ADX92639 (30 mg/kg, suspended in 1 % carboxy-
methylcellulose) or vehicle. ADX92639 and vehicle
were administered three times at time 0, and then
after 24 and 48 h. The rectal temperature was mea-
sured at different times after the first administration
of either ADX92639 or vehicle (see Table 1) by a
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thermistor inserted about 2 cm into the rectum. The
probe was left in place for about 10 sec.
Drug treatments in 4-VO rats
Twenty-six 4-VO rats satisfying the inclusion criteria
(loss or righting reflex, no response to painful stimuli,
and midriasis during carotid artery occlusion), and 8
sham operated rats were used for pharmacological ex-
periments. Two groups of 4-VO rats (n = 8 per group)
received oral administration of ADX92639 (30 mg/kg,
suspended in 1 % carboxymethylcellulose) or vehicle.
ADX92639 or vehicle were administered three times in
the post-ischemic period at 12, 36 and 60 h after reper-
fusion. Three sham-operated rats receving three oral
administration of 1 % carboxymethylcellulose at the
same time-points were used as controls. No sham op-
erated rats received ADX92639. Two additional
groups of 4-VO rats (n = 5 per group) were injected
s.c. with either LY487379 (30 mg/kg, dissolved in ara-
chid oil) or vehicle at 12, 24, 36, 48 and 60 h after
reperfusion. Sham-operated rats were treated s.c. with
either LY487379 (n = 2) or vehicle (n = 3) at the same
time-points. All animals were killed at 72 h after re-
perfusion for histological assessment of neuronal
death in the CA1 and CA3 regions.
Abbreviations
4-VO: 4-vessel occlusion; PAM: positive allosteric modulator; NAM: negative
allosteric modulator.
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